32
Participants
Start Date
October 31, 2010
Primary Completion Date
October 31, 2011
Study Completion Date
October 31, 2011
JNJ-32729463
150 mg intravenous formulation administered twice daily for at least 72 hours, followed by 250 mg oral formulation administered twice daily for a total treatment time of 7 to 14 days
moxifloxacin
400 mg intravenous formulation administered once daily for at least 72 hours, followed by 400 mg oral formulation administered once daily for a total treatment time of 7 to 14 days. To maintain the blind, subjects will receive one dose of moxifloxacin and one dose of placebo daily.
JNJ-32729463 (Open-Label)
Subjects may receive JNJ-32729463 intravenous formulation up to 150 mg either BID or TID followed by 250 mg oral formulation BID for a total treatment time of 7 to 14 days.
Furiex Research Site, Tatabánya
Furiex Research Site, Gyöngyös
Furiex Research Site, Miskolc
Furiex Research Site, Debrecen
Furiex Research Site, Csorna
Furiex Research Site, Greifswald
Furiex Research Site, Hanover
Furiex Research Site, Orlando
Furiex Research Site, Vero Beach
Furiex Research Site, Paderborn
Furiex Research Site, Mobile
Furiex Research Site, Hazard
Furiex Research Site, Anaconda
Furiex Research Site, Peoria
Furiex Research Site, Hofheim
Furiex Research Site, Homburg/Saar
Furiex Research Site, Omaha
Furiex Research Site, Austin
Furiex Research Site, Austin
Furiex Research Site, Austin
Furiex Research Site, Albueuerque
Furiex Research Site, Sylmar
Furiex Research Site, Longview
Furiex Research Site, Calgary
Furiex Research Site, Chicoutimi
Furiex Research Site, Québec
Furiex Research Site, Bogotá
Furiex Research Site, Santiago de Cali
Furiex Research Site, Bialystok
Furiex Research Site, Bydgoszcz
Furiex Research Site, Bystra
Furiex Research Site, Lodz
Furiex Research Site, Skierniewice
Furiex Research Site, Warsaw
Lead Sponsor
Furiex Pharmaceuticals, Inc
INDUSTRY